ライフサイエンスコーパス: neonatal mortality

1 d lead to a reduction of the order of 25% in neonatal mortality.

2 .6% (95%CI 3.4-11.7; p = 0.001) reduction in neonatal mortality.

3 t-dependent glycogen synthesis and increased neonatal mortality.

4 defect worldwide and are a leading cause of neonatal mortality.

5 of PE, placenta-mediated complications, and neonatal mortality.

6 g countries to identify strategies to reduce neonatal mortality.

7 available or feasible in countries with high neonatal mortality.

8 atal mortality and 1.90 (1.32-2.73) for post-neonatal mortality.

9 ion of maternal cancer during pregnancy with neonatal mortality.

10 atal mortality and 2.50 (1.48-4.22) for post-neonatal mortality.

11 to SSRIs during pregnancy and stillbirth or neonatal mortality.

12 ca achieved marked reductions in under-5 and neonatal mortality.

13 ciated with preterm birth, fetal injury, and neonatal mortality.

14 (SSRIs) increases the risk of stillbirth or neonatal mortality.

15 ulted in acute respiratory distress and high neonatal mortality.

16 ight, and a Poisson model for the outcome of neonatal mortality.

17 hand washing, and appropriate cord care) and neonatal mortality.

18 l ultrasound or neonatal assessment, and (3) neonatal mortality.

19 Few data exist for neonatal mortality.

20 oducing mucus obstruction, inflammation, and neonatal mortality.

21 al Bangladesh, which has a moderate level of neonatal mortality.

22 nment organisation infrastructures to reduce neonatal mortality.

23 a, aimed at modifying practices and reducing neonatal mortality.

24 health system, low health-care use, and high neonatal mortality.

25 al behavioural modification and reduction in neonatal mortality.

26 The primary outcome was reduction in neonatal mortality.

27 CDH remains a significant cause of neonatal mortality.

28 rd reduces local cord infections and overall neonatal mortality.

29 but fatal outcomes, including stillbirth and neonatal mortality.

30 es were incidence of neonatal omphalitis and neonatal mortality.

31 plications of prematurity are main causes of neonatal mortality.

32 which this community intervention may affect neonatal mortality.

33 er effect is seen in settings with very high neonatal mortality.

34 not be met without substantial reductions in neonatal mortality.

35 bstetric intervention, and case mix-adjusted neonatal mortality.

36 Birth weight-adjusted neonatal mortality.

37 e number of neonatal intensive care beds and neonatal mortality.

38 intensive care beds is associated with lower neonatal mortality.

39 Similar results were also seen for neonatal mortality.

40 ause significant morbidity and even fetal or neonatal mortality.

41 The primary outcome was neonatal mortality.

42 ), birth injury, low Apgar score (</=8), and neonatal mortality.

43 , and PGF2alpha, resulting in PTB and marked neonatal mortality.

44 ntly 10.7% of under-5 mortality and 15.1% of neonatal mortality.

45 The primary outcome was all-cause neonatal mortality.

46 wed a reduction of 8% (95% CI -12 to 25%) in neonatal mortality.

47 itated by ASHAs on birth outcomes, including neonatal mortality.

48 re cannot be expected to reduce maternal and neonatal mortality.

49 resulted in very low levels of maternal and neonatal mortality.

50 but less progress has been made in reducing neonatal mortality.

51 (VD) that was associated with an increase in neonatal mortality.

52 association of facility quality of care with neonatal mortality.

53 ceramide (alpha-GalCer) induced late PTB and neonatal mortality.

54 affected by vesicular disease and increased neonatal mortality.

55 weight loss before pregnancy reduced risk of neonatal mortality.

56 ermine factors associated with postoperative neonatal mortality.

57 ctive hospital-based interventions to reduce neonatal mortality.

58 ity (0.45, 0.17-0.73) and a 33% reduction in neonatal mortality (0.67, 0.59-0.74).

59 0.63, 95% CI 0.32-0.94), a 23% reduction in neonatal mortality (0.77, 0.65-0.90), and a 9% non-signi

60 ed initiation of breastfeeding and increased neonatal mortality (2-28 d) were recently reported in ru

61 cline from 1990 to 2010 is 2.1% per year for neonatal mortality, 2.3% for postneonatal mortality, and

62 before; there was a significant decrease in neonatal mortality (9% to 0%; P=.01) and a trend toward

63 In the mid-2000s, neonatal mortality accounted for almost 40% of deaths of

64 Neonatal mortality accounts for 43% of global under-five

65 Neonatal mortality accounts for 43% of under-five mortal

66 Neonatal mortality accounts for a high proportion of dea

67 was associated with a relative reduction in neonatal mortality (adjusted odds ratio 0.52, 95% CI 0.3

68 es is associated with relative reductions in neonatal mortality among home births in underserved, rur

69 very kit use or clean delivery practices and neonatal mortality among home births.

70 The primary outcome was 28-day neonatal mortality among infants less than the 5th perce

71 We examined differences in neonatal mortality among infants with very low birth wei

72 Neonatal mortality among preterm Whites dropped 34% duri

73 irths were associated with lower maternal or neonatal mortality among WHO member states.

74 population) were 1.83 (95% CI 1.34-2.50) for neonatal mortality and 1.90 (1.32-2.73) for post-neonata

75 or preterm were 6.82 (95% CI 3.56-13.07) for neonatal mortality and 2.50 (1.48-4.22) for post-neonata

76 eks' gestation), which is a leading cause of neonatal mortality and birth-related morbidity.

77 major demographic metrics (adult mortality, neonatal mortality and birthrate) between the two period

78 henomena related to premature birth, such as neonatal mortality and cerebral palsy.

79 were used to explore the association between neonatal mortality and clean delivery kit use or clean d

80 Preterm delivery is the leading cause of neonatal mortality and contributes significantly to infa

81 c-Abl-null mice show high neonatal mortality and decreased B lymphocytes, whereas

82 is associated with substantial reductions in neonatal mortality and low birthweight under routine mal

83 nets are associated with a decreased risk of neonatal mortality and lower birth-weight.

84 ough umbilical cord infection contributes to neonatal mortality and morbidity and risk can be reduced

85 extreme prematurity is the leading cause of neonatal mortality and morbidity due to a combination of

86 and remains a leading cause of maternal and neonatal mortality and morbidity in the United States an

87 Sepsis is a major cause of neonatal mortality and morbidity worldwide.

88 Preterm birth is the major cause of neonatal mortality and morbidity, and bacterial infectio

89 the scope of midwifery; reduced maternal and neonatal mortality and morbidity, reduced stillbirth and

90 Preterm birth (PTB) is the leading cause of neonatal mortality and morbidity, with few prevention an

91 m labor (PTL), associated with high rates of neonatal mortality and morbidity.

92 ant factor contributing to preterm birth and neonatal mortality and morbidity.

93 event early preterm birth and its associated neonatal mortality and morbidity.

94 We also compared changes in neonatal mortality and newborn care practices in interve

95 cleansing with 4% chlorhexidine solution on neonatal mortality and omphalitis in rural settings of s

96 Outcomes of interest included maternal and neonatal mortality and other intermediate measures such

97 ection-associated PTB, 101.10 prevented PTB, neonatal mortality, and fetal brain inflammation.

98 ratios for spontaneous abortion, stillbirth, neonatal mortality, and infant mortality were estimated

99 Preterm birth is the leading cause of neonatal mortality, and is frequently associated with in

100 nt Goal 2030 targets for maternal mortality, neonatal mortality, and mortality in children younger th

101 with HLHS born far from a CSC have increased neonatal mortality, and most of this mortality is presur

102 h interventions coverage, under-5 mortality, neonatal mortality, and prevalence of under-5 stunting.

103 predictors of effect on maternal mortality, neonatal mortality, and stillbirths.

104 Preterm birth (PTB) is the leading cause of neonatal mortality, and surviving infants are at increas

105 eptococcal infections are a leading cause of neonatal mortality, and they also affect pregnant women

106 However, prenatal and neonatal mortalities are significantly increased in Gcn2

107 tudies, particularly from settings with high neonatal mortality, are needed to determine whether targ

108 y rates were not correlated with maternal or neonatal mortality at a country level.

109 d deaths to produce estimates of under-5 and neonatal mortality at a resolution of 5 x 5 km grid cell

110 00 live births) or neonatal mortality rates (neonatal mortality before age 28 days per 1000 live birt

111 Neonatal mortality before discharge from the hospital.

112 oglycemia, hypotriglyceridemia, wasting, and neonatal mortality between days 2 and 14.

113 wed significant reductions in stillbirth and neonatal mortality but did not report the overall effect

114 munity mobilisation interventions may reduce neonatal mortality but the contribution of referral comp

115 t beta3-deficient mice die as neonates; some neonatal mortality, but not all, is accompanied by cleft

116 of pregnancy and delivery complications and neonatal mortality, but the mechanisms are unclear.

117 substantial and growing share of under-5 and neonatal mortality, but they are largely neglected in th

118 n of low-birth-weight (LBW) newborns reduces neonatal mortality by >40% due to prevention of primaril

119 mme settings in Ghana and south Asia reduced neonatal mortality by 12% (95% CI 5-18).

120 al to test whether early BCG-Denmark reduces neonatal mortality by 45%.

121 estation days 15-18) significantly increased neonatal mortality by preventing closure of the DA after

122 ce and the risk ratio between SGA status and neonatal mortality, calculated using Poisson regression

123 tetanus are important causes of maternal and neonatal mortality, claiming about 180 000 lives worldwi

124 an intention-to-treat analysis comparing the neonatal mortality (day 0-27) per 1,000 live births in i

125 We examine neonatal mortality (death within the first 28 days after

126 the year after pregnancy were noted for both neonatal mortality (deaths within 0 to 27 days; IRR, 2.7

127 cline occurred in the 1-59 months age group; neonatal mortality declined more slowly (from 50 to 23 d

128 tion in rural Bangladesh showed no effect on neonatal mortality, despite a similar intervention havin

129 thweight infants in the intervention groups, neonatal mortality did not decrease in this group, and i

130 Louis area; we then compared neonatal mortality during two periods, one before and on

131 al mortality ratio, and under-5, infant, and neonatal mortality, especially in socioeconomically disa

132 Neonatal mortality fell by 51% from 16.2 deaths per 1000

133 comes were defined as spontaneous abortions, neonatal mortality, fetal deaths, admission to the neona

134 Secondary outcomes were neonatal mortality, fetal loss (abortions and stillbirth

135 We developed new estimates of child and neonatal mortality for 1998-2009 using a 2010 household

136 provided significantly greater reductions in neonatal mortality for female neonates compared with mal

137 Risk-adjusted neonatal mortality for infants born in smaller level III

138 Increases in neonatal mortality for infants born on the weekend were

139 We estimated child and neonatal mortality for the years 2000-14 using five dist

140 but also renal tubular defects that lead to neonatal mortality from renal failure.

141 f neonatal deaths and increases risk of post-neonatal mortality, growth failure, and adult-onset non-

142 Reduction of neonatal mortality has been slower than that for materna

143 therapy for RDS became generally available, neonatal mortality improved more for white than for blac

144 erogeneity in absolute levels of under-5 and neonatal mortality in 2015, as well as the annualised ra

145 and used them to project rates of child and neonatal mortality in 2035 in 74 Countdown to 2015 prior

146 d driving time) from birth center to CSC and neonatal mortality in 463 infants with HLHS.

147 eonatal breastfeeding) on infection-specific neonatal mortality in breastfed neonates aged 2-28 d.

148 rative newborn care is effective in reducing neonatal mortality in communities with a weak health sys

149 Preterm birth, the major cause of neonatal mortality in developed countries, is associated

150 The neonatal mortality in heterozygote offspring of CRBP II(

151 s/litter) was increased as compared with the neonatal mortality in heterozygote offspring of wild typ

152 ework by applying it to the case of reducing neonatal mortality in India.

153 Neonatal mortality in infants born <10 minutes from a CS

154 A number of cases of neonatal mortality in infants who were at risk for adPHA

155 INTERPRETATION: The reduction in neonatal mortality in intervention clusters occurred aga

156 ate the association of facility quality with neonatal mortality in Malawi.

157 Chlorhexidine umbilical cord washes reduce neonatal mortality in south Asian populations with high

158 number of outbreaks of vesicular disease and neonatal mortality in swine.

159 Neonatal mortality in the subgroup of HLHS patients with

160 rt the use of chlorhexidine for reduction of neonatal mortality in this east African setting, which m

161 ed to compare the odds ratios for infant and neonatal mortality in treated and intreated areas.

162 breastfeeding and reduced infection-specific neonatal mortality in young human infants.

163 Observed neonatal mortality increased from 2.80 per 1000 weekday

164 were associated with increased rates of post-neonatal mortality, infant mortality, and under-5 mortal

165 Neonatal mortality is the biggest contributor to global

166 ity health workers in reducing perinatal and neonatal mortality is well established, evidence in supp

167 inistration (FDA) in 1990 might have reduced neonatal mortality more among whites than among blacks.

168 fant mortality was similar to the 2%-4% post-neonatal mortality observed in this region.

169 associated with a 16% relative reduction in neonatal mortality (odds ratio 0.84, 95% CI 0.77-0.92).

170 er day had significantly lower risk-adjusted neonatal mortality (odds ratio, 0.62; 95% confidence int

171 1 per 1000 in control areas), a reduction in neonatal mortality of 38% (risk ratio, 0.62 [95% CI, 0.4

172 l and child healthcare led to a reduction in neonatal mortality of almost the hypothesized 25% in sma

173 t or highly restrictive atrial septum face a neonatal mortality of at least 48% despite early postnat

174 Comparing the neonatal mortality of infants born on weekdays and weeke

175 nificantly increased risk of pregnancy loss, neonatal mortality, or malformation.

176 effects and no benefit for gestation length, neonatal mortality, or placental inflammation.

177 RIs during pregnancy and risk of stillbirth, neonatal mortality, or postneonatal mortality.

178 The primary outcome was neonatal mortality over a 2 year follow up.

179 Average rates of infant, neonatal, and post-neonatal mortality over the study period were 55.2, 30.7

180 -level heterogeneity in under-5, infant, and neonatal mortality over time in Mozambique.

181 sociated with reduction in both maternal and neonatal mortality (p=0.026 and p=0.011, respectively).

182 to entirely rescue the previously described neonatal mortality phenotype despite the animals having

183 ns can reduce the three most common cause of neonatal mortality--preterm, intrapartum, and infection-

184 nificantly associated with decreased risk of neonatal mortality (protective efficacy [PE] 18%, 95% CI

185 -10.1; 95% CI, -16.8 to -3.4; P = .003) and neonatal mortality rate (adjusted slope coefficient, -0.

186 ssociated with a nonsignificant reduction in neonatal mortality rate (MRR, 0.70; 95% confidence inter

187 Africa by assessing the effect on all-cause neonatal mortality rate (NMR) and essential newborn-care

188 rates and maternal mortality ratio (MMR) and neonatal mortality rate (NMR) were inversely correlated.

189 The neonatal mortality rate among all very-low-birth-weight

190 We found no significant difference in neonatal mortality rate between the chlorhexidine group

191 cluded changes in newborn-care practices and neonatal mortality rate compared with the control group.

192 The neonatal mortality rate during this period was 30 per 10

193 The neonatal mortality rate in Andhra Pradesh was 44 per 1,0

194 ity rate is 46 per 1000 live births, and the neonatal mortality rate is 33 per 1000 live births.

195 increased from $127 per life-year saved at a neonatal mortality rate of 60 deaths per 1000 livebirths

196 ive for lower-middle-income countries in all neonatal mortality rate scenarios modelled, and at least

197 The neonatal mortality rate was 11.78 (95% CI 5.92-23.46) pe

198 ong the 6,686 neonates analyzed, the overall neonatal mortality rate was 17 per 1,000 live births.

199 tal death rate was 45.6 per 1000 births, the neonatal mortality rate was 29.3 per 1000 live births, a

200 e term (at 26 to 36 weeks of gestation), the neonatal mortality rate was 315 per 1000 for infants wit

201 The neonatal mortality rate was 42 deaths per 1000 livebirth

202 Neonatal mortality rate was compared with generalised es

203 Neonatal mortality rate was most strongly associated wit

204 Compared with controls, neonatal mortality rate was reduced by 54% in the essent

205 The neonatal mortality rate was significantly lower in the i

206 The final model included log(neonatal mortality rate) (cubic spline), log(low birthwe

207 unt rate, protective effectiveness, baseline neonatal mortality rate, and implementation costs.

208 (HSA) level variation in the expected early neonatal mortality rate, based on gestational age (GA) a

209 h (day 0) and within week 1 varied little by neonatal mortality rate, income, or region.

210 Heterogeneity was greater for neonatal mortality rate, with only seven of 11 provinces

211 nce with singletons was especially stark for neonatal mortality (rate ratio 5.0, 95% CI 4.5-5.6).

212 days postpartum per 100,000 live births) or neonatal mortality rates (neonatal mortality before age

213 Neonatal mortality rates (NMRs) in countries of low and

214 etal and infant death certificates to assess neonatal mortality rates among 48,237 very-low-birth-wei

215 rtality in south Asian populations with high neonatal mortality rates and predominantly home-based de

216 ish the trends in U5MR from which infant and neonatal mortality rates are generally derived.

217 n Africa has the world's highest under-5 and neonatal mortality rates as well as the highest naturall

218 By producing under-5 and neonatal mortality rates at multiple levels of geospatia

219 ffect of chlorhexidine with dry cord care on neonatal mortality rates in Zambia.

220 rd applications did not significantly reduce neonatal mortality rates in Zambia.

221 he potential cost-effectiveness for baseline neonatal mortality rates of 20-60 deaths per 1000 livebi

222 y cost effective for low-income countries at neonatal mortality rates of 30 or more deaths per 1000 l

223 The number of countries with neonatal mortality rates of fewer than 11 per 1000 liveb

224 If all high-burden countries achieved the neonatal mortality rates of their region's fastest progr

225 r sub-Saharan African populations with lower neonatal mortality rates or mostly facility-based delive

226 Maternal and neonatal mortality rates remain high in many low-income

227 last 6 months of the 30-month intervention, neonatal mortality rates were 29.2 per 1000, 45.2 per 10

228 infants receive early BCG in areas with high neonatal mortality rates.

229 s and lower (<30 deaths per 1000 livebirths) neonatal mortality rates.

230 the population and targeting continued high neonatal mortality rates.

231 Neonatal mortality reduced from 35.0 to 30.5 deaths per

232 ch trends and subnational variation in early neonatal mortality reflect differences in the prevalence

233 Neonatal mortality remained high despite better care pra

234 We modelled daily neonatal mortality risk and estimated the proportion of

235 Our objective was to estimate the neonatal mortality risk associated with preterm birth wh

236 The pooled neonatal mortality risk did not differ significantly; th

237 The neonatal mortality risk of babies who were both preterm

238 st risk of neonatal death, with ongoing post-neonatal mortality risk, and important risk of long-term

239 and no significant change in the associated neonatal mortality risk, resulting in a decrease in the

240 h are the most risky for human survival, yet neonatal mortality risks are generally not reported by d

241 stillbirth (RR = 6.3, 99% CI: 4.7, 7.9), and neonatal mortality (RR = 7.6, 99% CI: 5.2, 10.1).

242 Seven studies (8.4%) were from high neonatal mortality settings.

243 Between 1990 and 2010, the U.S ranking in neonatal mortality slipped from 29(th) to 45(th) among c

244 0 live births were inversely correlated with neonatal mortality (slope coefficient, -1.4; 95% CI, -2.

245 Reductions in neonatal mortality that exceed 50% can be achieved with

246 ventions that need to be scaled up to reduce neonatal mortality, there is a lack of clarity on the in

247 ASHAs can successfully reduce neonatal mortality through participatory meetings with w

248 t of CD71(+) erythroid splenocytes on murine neonatal mortality to endotoxin challenge or polymicrobi

249 rom foetal akinesia resulting in in utero or neonatal mortality, to milder disorders that are not lif

250 d postnatal packages have similar effects on neonatal mortality--two-fold to three-fold greater than

251 p or ITNs) at preventing low birthweight and neonatal mortality under routine programme conditions in

252 e tested the association between kit use and neonatal mortality using a pooled dataset from all three

253 stillbirths was 0.45%, and the incidence of neonatal mortality was 0.34%.

254 ensives, the APO rate was 58.0% and fetal or neonatal mortality was 22.0%.

255 the less-than-5th-percentile infants, 28-day neonatal mortality was 225 per 1000 livebirths for the i

256 Neonatal mortality was 24% lower in the chlorhexidine gr

257 Among the whole population, 28-day neonatal mortality was 27.4 per 1000 livebirths for the

258 Maternal-fetal-neonatal mortality was determined not only by acuteness

259 Neonatal mortality was not associated with SSRI first-tr

260 Finally, an increased prevalence in neonatal mortality was observed in litters from dams lac

261 Neonatal mortality was reduced in the home-care arm by 3

262 Risk-adjusted neonatal mortality was significantly lower for births th

263 irth rates so that the percentage decline in neonatal mortality was similar in the two racial groups

264 Independent predictors of maternal-fetal-neonatal mortality were Acute Physiology and Chronic Hea

265 s of preterm delivery, low birth weight, and neonatal mortality were compared for women with low CD4

266 loped more complications; maternal and fetal-neonatal mortality were higher.

267 Community-based interventions can reduce neonatal mortality when health systems are weak.

268 ated with neurodegeneration and prenatal and neonatal mortality, which could be due to excess cell de

269 cal factor and climate factors for adult and neonatal mortality, while birthrate was not affected by

270 Preterm birth is a leading cause of neonatal mortality, with a variety of contributing cause

271 over, Speg mutant mice exhibited significant neonatal mortality, with increased death occurring by 2

272 PLA improve key behaviours on the pathway to neonatal mortality, with the strongest evidence for home

273 ity within 28 days post-partum and all-cause neonatal mortality within 28 days post-partum among babi

274 The primary outcomes were all-cause neonatal mortality within 28 days post-partum and all-ca

275 III NICU care has the potential to decrease neonatal mortality without increasing costs.